ClinicalTrials.gg
CompletedNCT01915693ROCSUpdated Jun 4, 2019

ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study

A Phase 3 interventional study of Radiotherapy in Oesophageal Cancer, sponsored by Lisette Nixon. Completed at 17 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-06-04.

Sponsored by Lisette Nixon · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Esophageal Neoplasms with a site in United Kingdom — 25 open to participants now, 34 under way, 3 of them phase 3. Esophageal Neoplasms · United Kingdom.

Planned enrollment
25th of 73
220 · median 100
Started
2013
with 7 others
Phase 3
11 of 111
2 open now
Registered
34th of 111
by date
Lead sponsor
3 of 111
Lisette Nixon

Among the 111 studies in Esophageal Neoplasms with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2013, is one of 11 in phase 3, and was the 34th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

25 of the 111 studies in Esophageal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Esophageal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The single most distressing symptom for more than 70% of patients with oesophageal cancer is difficulty in swallowing (dysphagia) caused by blockage of the gullet by a tumour. This causes severe restrictions on food intake, physical activity, social functioning and overall quality of life. Amongst the more effective treatments for improving swallowing, is the insertion of a metal stent across the blocked part, which then self-expands to open up the gullet (Self Expanding Metal Stent or SEMS). The addition of radiotherapy may help to improve the problems caused by dysphagia and provide an additional survival benefit.

The purpose of this study is to test the impact of adding radiotherapy to SEMS on:

  • the length of time swallow remains improved for
  • quality of life
  • survival
Read the detailed description

The primary objective of the study is to assess the impact of radiotherapy in addition to self-expanding metal stent (SEMS) placement on time to progression of patient-reported dysphagia in a patient population unable to undergo surgery.

Patients will be eligible to take part in the trial if they have oesophageal cancer, are in need of SEMS because of dysphagia, are aged 16 years or older, have been clinically assessed to be able to receive radiotherapy, have an expected survival of at least 12 weeks and are able to give written informed consent.

496 patients will be randomised to receive either SEMS alone or SEMS with radiotherapy. The radiotherapy will be given as an outpatient either as five treatments (one per day) over one week, or ten treatments over two weeks. Questionnaires will be completed before treatment, and at weeks two and four and then monthly for up to one year to assess quality of life and cost effectiveness. Interviews will be held with trial participants at three time points to explore their experiences while on the trial. Interviews will also be held with patients who do not consent to take part in the trial to explore their reasons for non-consent.

Treatments:

Arm A: Self-expanding metal stents (SEMS) (Control Arm) SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.

Arm B: SEMS plus external beam radiotherapy (Intervention Arm) External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.

There will also be a qualitative component of the trial will have two aims: i) to explore the feasibility of patients' recruitment to the trial and ii) to explore participants' experience of the trial interventions. It will examine their experience of consent and recruitment including reasons for declining, and examine patients' motivation to accept randomisation to an intervention which may include extra radiotherapy. This is an optional component and will require separate consent. Patients who do not consent to the trial, but who do consent to the qualitative component, will be interviewed about their reasons for not-consenting as soon as possible after the approach to participate.

Trial participants who consent to the qualitative component will be interviewed three times: at weeks one and four to capture initial decision-making thoughts and then after the interventions (week 8) to explore patients' experience of interventions and perceptions of benefit or detriment.

03

Conditions studied

  • Oesophageal Cancer

Keywords

  • Radiotherapy
  • stent
  • quality of life
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological confirmation of oesophageal carcinoma excluding small cell histology
  2. Not suitable for radical treatment (oesophagectomy or radical chemoradiotherapy) either because of patient choice or medical reasons
  3. Dysphagia clinically assessed as needing stent as primary treatment of the dysphagia
  4. Age 16 years or over
  5. Discussion and treatment decision for stent placement made by an upper GI multi-disciplinary team
  6. Clinician assessment of ability to attend for radiotherapy
  7. Expected survival of at least 12 weeks
  8. Written
  9. Patient has completed baseline Quality of Life Questionnaires (please note, as a minimum patients must have completed OG25)

Exclusion criteria

Exclusion Criteria:

  1. Histology of small cell carcinoma type
  2. Tumour length of greater than 12 cm
  3. Tumour growth within 2 cm of the upper oesophageal sphincter
  4. Endoscopic treatment of the tumour, other than dilatation, planned in the peri-stent period
  5. Presence of a tracheo-oesophageal fistula
  6. Presence of a pacemaker in proposed radiotherapy field
  7. Previous radiotherapy to the area of the proposed radiotherapy field
  8. Planned endoscopic treatment of the tumour (e.g. laser) in the immediate peri-stenting period
  9. Female patient who is pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • No intervention
    Arm A: Self-expanding metal stents (SEMS) (Control Arm)

    SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.

  • Experimental
    Arm B: SEMS plus external beam radiotherapy (Intervention Arm)

    External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.

    Radiation: Radiotherapy

Interventions

  • RadiationRadiotherapy

    External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.

06

What researchers measure

Primary outcomes

  1. patient-reported dysphagia

    Assess the impact of radiotherapy in addition to self-expanding metal stent (SEMS) placement on time to progression of patient-reported dysphagia in a patient population unable to undergo surgery.

    Time frame: within one year

Secondary outcomes

  1. quality of life

    Assess the impact of combination treatment on core components of health related quality of life

    Time frame: within one year

  2. overall survival

    Assess the impact of radiotherapy in addition to SEMS placement on overall survival

    Time frame: one year

  3. morbidity

    Measure morbidity associated with the interventions

    Time frame: one year

  4. re-intervention rate

    Measure re-intervention rates

    Time frame: one year

  5. cost

    Assess the cost of the addition of radiotherapy to SEMS placement

    Time frame: one year

07

Study locations

17 sites
  • Bristol Haematology and Oncology Centre
    Bristol, England BS2 8ED, United Kingdom
  • Doncaster Royal Infirmary
    Doncaster, England DN2 5LT, United Kingdom
  • James Cook University Hospital
    Middlesbrough, England TS4 3BW, United Kingdom
  • George Eliot Hospital
    Nuneaton, England CV10 7DJ, United Kingdom
  • Conquest Hospital
    Saint Leonards-on-Sea, England TN37 7RD, United Kingdom
  • Cancer Research Centre at Weston Park Hospital
    Sheffield, England S1O 2SJ, United Kingdom
  • Musgrove Park Hospital
    Taunton, England TA1 5DA, United Kingdom
  • Southend University Hospital NHS Foundation Trust
    Westcliff-On-Sea, England SS0 0RY, United Kingdom
  • Weston General Hospital
    Weston-super-Mare, England BS23 4TQ, United Kingdom
  • Ninewells Hospital
    Dundee, Scotland DD1 9SY, United Kingdom
  • Ysbyty Gwynedd
    Bangor, Wales LL57 2PW, United Kingdom
  • Velindre Cancer Center at Velindre Hospital
    Cardiff, Wales CF14 2TL, United Kingdom
  • Royal Gwent Hospital
    Newport Gwent, Wales NP9 2UB, United Kingdom
  • Glan Clwyd Hospital
    Rhyl, Denbighshire, Wales LL 18 5UJ, United Kingdom
  • Wrexham Maelor Hospital
    Wrexham, Wales LL13 7TD, United Kingdom
  • Weston Park Hospital
    Sheffield, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
08

References and documents

Publications

  • Adamson D, Blazeby J, Porter C, Hurt C, Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons D, Nixon L, Fitzgibbon J, Thomas S, Millin A, Crosby T, Staffurth J, Byrne A. Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT. Health Technol Assess. 2021 May;25(31):1-144. doi: 10.3310/hta25310. PubMed 34042566 ↗
  • Adamson D, Byrne A, Porter C, Blazeby J, Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons D, Nixon L, Fitzgibbon J, Thomas S, Millin A, Crosby T, Staffurth J, Hurt C. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):292-303. doi: 10.1016/S2468-1253(21)00004-2. Epub 2021 Feb 19. Erratum In: Lancet Gastroenterol Hepatol. 2021 Apr;6(4):e3. doi: 10.1016/S2468-1253(21)00069-8. PubMed 33610215 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Nov 2018, 61 months.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's 61 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2013
First posted
Aug 5, 2013
StartActual
Oct 2013
Primary completionActual
Nov 2018
CompletionActual
Nov 2018
Last update
Jun 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01915693
Lead sponsor
Lisette Nixon
Responsible party
Lisette Nixon (Senior Trial Manager, Velindre NHS Trust) — Sponsor-investigator
First posted
Aug 5, 2013
Start date
Oct 2013
Primary completion
Nov 2018
Completion
Nov 2018
Last update
Jun 4, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion